Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Affiliations

Science Blogs
ACI Profile for Alan Kotok
Featured in Alltop

Tissue Regeneration Start-Up Gains $33M in Early Funds

A new enterprise founded by researchers at Stanford University aims to discover and develop drugs that repair and regenerate tissue from stem cells. . . . → Read More: Tissue Regeneration Start-Up Gains $33M in Early Funds

Biotechs License Solid Tumor Therapy in $2.1B Deal

Biotechnology enterprise Immunomedics Inc. is licensing its enhanced antibody-based treatment for solid tumor cancers to Seattle Genetics, a developer of similar cancer drugs. . . . → Read More: Biotechs License Solid Tumor Therapy in $2.1B Deal

Univ. Spin-Off Offering Pediatric Care Software

A company spun-off from Indiana University is marketing software written in its medical school to relate pediatric clinical guidelines to parents’ concerns during office visits. . . . → Read More: Univ. Spin-Off Offering Pediatric Care Software

Protein Drug Discovery Company Launches, Gains $50M

A biotechnology enterprise founded by faculty at Scripps Research Institute plans to discover new therapies based on complex interactions with human proteins. . . . → Read More: Protein Drug Discovery Company Launches, Gains $50M

Simpler Lab Cell Production Techniques Devised

A process is being developed that makes it easier to produce healthy and diseased cells in the lab from human specimens for regenerative medicine and research. . . . → Read More: Simpler Lab Cell Production Techniques Devised

Scripps, Pfizer Collaborate on DNA-Coded Drug Discovery

Drug maker Pfizer Inc. is gaining access to advances in a synthetic chemistry technology developed by Scripps Research Institute that tags compounds with DNA identifiers. . . . → Read More: Scripps, Pfizer Collaborate on DNA-Coded Drug Discovery

Sanofi Licensing Antibody for Autoimmune Diseases

The global drug company Sanofi is licensing a synthetic antibody to treat autoimmune disorders being developed by a spin-off enterprise from Dartmouth College. . . . → Read More: Sanofi Licensing Antibody for Autoimmune Diseases

Ionis Options Cardiac Drugs in $1.5 Billion Deal

Biotechnology company Ionis Pharmaceuticals is providing drug maker Novartis first access to two experimental drugs for controlling proteins that promote cholesterol and triglycerides, which contribute to heart disease. . . . → Read More: Ionis Options Cardiac Drugs in $1.5 Billion Deal

Spin-Off Creates Enzyme to Prevent Celiac Disease

A spin-off enterprise from University of Washington is developing a synthetic enzyme that prevents dietary gluten from triggering symptoms of celiac disease. . . . → Read More: Spin-Off Creates Enzyme to Prevent Celiac Disease

Cell Biotech Gains Organoid Technology

A Canadian biotechnology enterprise is licensing a technology that generates organoids, three-dimensional clusters of cells from stem cells that can form into gastrointestinal organs. . . . → Read More: Cell Biotech Gains Organoid Technology